Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results. / Stroomberg, Hein Vincent; Larsen, S. Benzon; Lanthén, G. Samsø; Nielsen, T. Kjaer; Helgstrand, J. T.; Brasso, K.; Røder, A.

In: Journal of Medical Systems, Vol. 47, No. 1, 98, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Stroomberg, HV, Larsen, SB, Lanthén, GS, Nielsen, TK, Helgstrand, JT, Brasso, K & Røder, A 2023, 'Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results', Journal of Medical Systems, vol. 47, no. 1, 98. https://doi.org/10.1007/s10916-023-01991-8

APA

Stroomberg, H. V., Larsen, S. B., Lanthén, G. S., Nielsen, T. K., Helgstrand, J. T., Brasso, K., & Røder, A. (2023). Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results. Journal of Medical Systems, 47(1), [98]. https://doi.org/10.1007/s10916-023-01991-8

Vancouver

Stroomberg HV, Larsen SB, Lanthén GS, Nielsen TK, Helgstrand JT, Brasso K et al. Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results. Journal of Medical Systems. 2023;47(1). 98. https://doi.org/10.1007/s10916-023-01991-8

Author

Stroomberg, Hein Vincent ; Larsen, S. Benzon ; Lanthén, G. Samsø ; Nielsen, T. Kjaer ; Helgstrand, J. T. ; Brasso, K. ; Røder, A. / Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results. In: Journal of Medical Systems. 2023 ; Vol. 47, No. 1.

Bibtex

@article{0a91cbd2a0a34cbc8655ee01eff67df5,
title = "Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results",
abstract = "In 2016, we introduced the Danish Prostate Cancer Registry (DaPCaR) which was built on the National Pathology Register from 1995 to 2011. DaPCaR was laborious to use as most data had to be manually imputed with no regular updates. In here we present a new comprehensive centralized prostate registry called the Danish Prostate Registry (DanProst), which includes all men having undergone any histological evaluation of prostate tissue merged with laboratory-, treatment-, prescription data as well as vital status. Here the data included and the methodology of DanProst are described. DanProst is built upon all men with a histological assessment of the prostate from the Danish National Registry for Pathology. The primary histology and potential prostate cancer histological diagnosis for each unique individual is extracted and translated by newly made algorithms for topography, procedure, diagnostic conclusion, and pathological staging. Further information is added from DaPCaR, the CPR Registry, the Danish Cause of Death Registry, the Danish Cancer Registry, the National Patient Registry, the Danish Register of Laboratory Results for Research, and the Danish National Prescription Registry. The translation algorithms were validated based on the comparison with DaPCaR in the period 2010–2016. DanProst includes 190,422 men. A total of 95,152 (50%) men are diagnosed with prostate cancer until 2021. Median diagnostic PSA was 11 ng/ml, most men are diagnosed by ultrasound-guided biopsy (N = 63,751; 67%), and most frequently defined primary treatment was radical prostatectomy (N = 14,778; 19%). DanProst to DaPCaR coherency was > 99%, 95%, and 94% for the primary histological procedure, primary histological conclusion, and diagnostic histological conclusion, respectively. DanProst is a continuously updated, centrally kept, validated registry with automatic integration of data from other national registries, allowing for contemporary nationwide analysis in men with histological assessment of the prostate.",
keywords = "DanProst, DaPCaR, Denmark, Prostate, Prostate cancer, Registry",
author = "Stroomberg, {Hein Vincent} and Larsen, {S. Benzon} and Lanth{\'e}n, {G. Sams{\o}} and Nielsen, {T. Kjaer} and Helgstrand, {J. T.} and K. Brasso and A. R{\o}der",
note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
doi = "10.1007/s10916-023-01991-8",
language = "English",
volume = "47",
journal = "Journal of Medical Systems",
issn = "0148-5598",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results

AU - Stroomberg, Hein Vincent

AU - Larsen, S. Benzon

AU - Lanthén, G. Samsø

AU - Nielsen, T. Kjaer

AU - Helgstrand, J. T.

AU - Brasso, K.

AU - Røder, A.

N1 - Publisher Copyright: © 2023, The Author(s).

PY - 2023

Y1 - 2023

N2 - In 2016, we introduced the Danish Prostate Cancer Registry (DaPCaR) which was built on the National Pathology Register from 1995 to 2011. DaPCaR was laborious to use as most data had to be manually imputed with no regular updates. In here we present a new comprehensive centralized prostate registry called the Danish Prostate Registry (DanProst), which includes all men having undergone any histological evaluation of prostate tissue merged with laboratory-, treatment-, prescription data as well as vital status. Here the data included and the methodology of DanProst are described. DanProst is built upon all men with a histological assessment of the prostate from the Danish National Registry for Pathology. The primary histology and potential prostate cancer histological diagnosis for each unique individual is extracted and translated by newly made algorithms for topography, procedure, diagnostic conclusion, and pathological staging. Further information is added from DaPCaR, the CPR Registry, the Danish Cause of Death Registry, the Danish Cancer Registry, the National Patient Registry, the Danish Register of Laboratory Results for Research, and the Danish National Prescription Registry. The translation algorithms were validated based on the comparison with DaPCaR in the period 2010–2016. DanProst includes 190,422 men. A total of 95,152 (50%) men are diagnosed with prostate cancer until 2021. Median diagnostic PSA was 11 ng/ml, most men are diagnosed by ultrasound-guided biopsy (N = 63,751; 67%), and most frequently defined primary treatment was radical prostatectomy (N = 14,778; 19%). DanProst to DaPCaR coherency was > 99%, 95%, and 94% for the primary histological procedure, primary histological conclusion, and diagnostic histological conclusion, respectively. DanProst is a continuously updated, centrally kept, validated registry with automatic integration of data from other national registries, allowing for contemporary nationwide analysis in men with histological assessment of the prostate.

AB - In 2016, we introduced the Danish Prostate Cancer Registry (DaPCaR) which was built on the National Pathology Register from 1995 to 2011. DaPCaR was laborious to use as most data had to be manually imputed with no regular updates. In here we present a new comprehensive centralized prostate registry called the Danish Prostate Registry (DanProst), which includes all men having undergone any histological evaluation of prostate tissue merged with laboratory-, treatment-, prescription data as well as vital status. Here the data included and the methodology of DanProst are described. DanProst is built upon all men with a histological assessment of the prostate from the Danish National Registry for Pathology. The primary histology and potential prostate cancer histological diagnosis for each unique individual is extracted and translated by newly made algorithms for topography, procedure, diagnostic conclusion, and pathological staging. Further information is added from DaPCaR, the CPR Registry, the Danish Cause of Death Registry, the Danish Cancer Registry, the National Patient Registry, the Danish Register of Laboratory Results for Research, and the Danish National Prescription Registry. The translation algorithms were validated based on the comparison with DaPCaR in the period 2010–2016. DanProst includes 190,422 men. A total of 95,152 (50%) men are diagnosed with prostate cancer until 2021. Median diagnostic PSA was 11 ng/ml, most men are diagnosed by ultrasound-guided biopsy (N = 63,751; 67%), and most frequently defined primary treatment was radical prostatectomy (N = 14,778; 19%). DanProst to DaPCaR coherency was > 99%, 95%, and 94% for the primary histological procedure, primary histological conclusion, and diagnostic histological conclusion, respectively. DanProst is a continuously updated, centrally kept, validated registry with automatic integration of data from other national registries, allowing for contemporary nationwide analysis in men with histological assessment of the prostate.

KW - DanProst

KW - DaPCaR

KW - Denmark

KW - Prostate

KW - Prostate cancer

KW - Registry

U2 - 10.1007/s10916-023-01991-8

DO - 10.1007/s10916-023-01991-8

M3 - Journal article

C2 - 37702859

AN - SCOPUS:85170671225

VL - 47

JO - Journal of Medical Systems

JF - Journal of Medical Systems

SN - 0148-5598

IS - 1

M1 - 98

ER -

ID: 368500344